NeuroPace (NPCE) has just closed out FY 2025 with Q4 revenue of US$26.6 million and a basic EPS loss of US$0.08, while trailing twelve month figures show revenue of US$100.0 million and a basic EPS loss of US$0.66 as the company continues to operate at a loss. Over the past several quarters, the business has seen revenue move from US$21.5 million in Q4 2024 to US$26.6 million in Q4 2025, with quarterly basic EPS losses ranging between US$0.18 and US$0.26 before the latest US$0.08 print. This puts the focus squarely on how quickly margins can tighten and losses can narrow from here.

See our full analysis for NeuroPace.

With the headline numbers on the table, the next step is to weigh them against the key stories investors follow around growth, profitability, and risk to see which narratives hold up and which look overstretched.

Losses Narrow On A US$21.5 Million TTM Improvement

• On a trailing basis, revenue has moved from US$79.9 million in Q4 2024 to US$100.0 million in Q4 2025, while the trailing net loss has shifted from US$27.1 million to US$21.5 million over the same periods.
• Bulls point to this combination of higher trailing revenue and a smaller trailing loss as early evidence of the long term earnings ramp they expect. However, the latest quarterly net loss of US$2.7 million in Q4 2025 versus US$5.3 million in Q4 2024 shows that, while the direction lines up with the bullish view, profitability is still not in sight and any path to the forecast earnings growth of about 44.24% per year will need several more periods with similar or better loss containment.
  • Supporters highlight that trailing revenue growth of roughly US$20.1 million over the last six quarters sits alongside a trailing loss that has narrowed by about US$5.7 million, which they see as consistent with a business scaling toward profitability.
  • The tension for bullish investors is that analysts are looking for revenue to grow around 14.4% per year and earnings to improve sharply, while the company still posted a quarterly loss in each of the last six quarters, so the recent trend needs to persist to match those expectations.

NeuroPace’s latest set of numbers is exactly what bullish investors have been watching for, so it is worth seeing how far their upside case goes with the full 🐂 NeuroPace Bull Case

P/S Premium And DCF Gap At Current US$13.95 Price

• At a share price of US$13.95, the company trades on a P/S ratio of 4.7x compared to 2.9x for the US Medical Equipment industry and 4.0x for peers, and the supplied DCF fair value of US$10.57 sits below the current price.
• Bears argue that paying a P/S premium and a price above the US$10.57 DCF fair value leaves little room for error when the trailing twelve month net loss is still US$21.5 million. This view leans on the idea that revenue running just under US$100.0 million and persistent basic EPS losses of US$0.66 over the last year do not yet justify a higher multiple than both the broader industry and peers.
  • Critics highlight that the roughly 4.7x P/S multiple sits around 60% higher than the 2.9x industry level, even though the company remains loss making on a trailing basis with no positive Basic EPS quarter in the data provided.
  • On top of that, the DCF fair value being about US$3.38 below the market price suggests investors are already paying up relative to one cash flow based model, which supports the cautious argument that valuation is ahead of the current financial profile.

Skeptical investors see this pricing tension as central to the cautious case, and the full bear-side breakdown sets out how that thesis builds from these numbers: 🐻 NeuroPace Bear Case

Analyst Upside Vs Ongoing Losses

• The supplied analyst data points to expected annual revenue growth of around 18.6% and an implied analyst price target of US$19.88, compared with the current share price of US$13.95 and a trailing loss of US$21.5 million on Basic EPS of US$0.66.
• Consensus narrative fans emphasize that this mix of higher projected growth and a price target about US$5.93 above the market suggests room for upside. Yet the fact that every quarter in the table still shows a loss, from US$2.7 million in Q4 2025 back to US$5.5 million in Q3 2024, means the company has to move from a loss making profile to the projected earnings of about US$17.4 million by 2028 for that scenario to line up with reality.
  • On one side, analysts expect revenue growth stronger than the wider US market at 14.4% per year and even faster in some bullish cases, which is part of why they see value above today’s price.

  Next Steps

  To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for NeuroPace on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

  If the mix of optimism and caution in this article feels familiar, this is the moment to look through the numbers yourself and move quickly to shape your own view. Start with our breakdown of 3 key rewards.

  See What Else Is Out There

  NeuroPace is still loss making with trailing net losses of US$21.5 million and quarterly EPS in the red, while trading at a P/S premium and above one DCF fair value estimate.

  If you want ideas that put more emphasis on valuation support and less on paying up for ongoing losses, our 47 high quality undervalued stocks can quickly surface alternatives that may better fit that preference.

  This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.